Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mizuho Kalabis"'
Autor:
Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third inter
Externí odkaz:
https://doaj.org/article/3a3ddc48ec6449b2b77882fcccc4b11b
Autor:
Erin Jensen, Evan J Lipson, Martin A Cheever, Adil Daud, Brent A Hanks, Shailender Bhatia, Thomas Olencki, Kari Kendra, Mizuho Kalabis, William H Sharfman, Ragini R Kudchadkar, Philip A Friedlander, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Candice Church, Tomoko Akaike, Michi M Shinohara, Bob Salim, Blanca Homet Moreno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current stu
Externí odkaz:
https://doaj.org/article/73de26009f964e2780583bb59aad23b0
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/1bfc61267f7a45059e87b4fee703575b
Publikováno v:
Immunotherapy. 14(4)
Background: Little is known regarding treatment patterns and overall survival (OS) for patients with advanced melanoma who progress after anti-PD-1 exposure. Methods: The Kaplan–Meier method was used to evaluate OS from electronic health records fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac074913462573af98a533bb5bbc2bd
https://pubmed.ncbi.nlm.nih.gov/34870445
https://pubmed.ncbi.nlm.nih.gov/34870445
Autor:
Daniela E. Myers, Lawrence F. Eichenfield, Mizuho Kalabis, Linda Stein Gold, Paul Sanders, Chuanbo Zang, Gil Yosipovitch, Joseph C. Cappelleri, Andrew G. Bushmakin, Melissa Olivadoti, Amy S. Paller, Bonnie Vlahos
Publikováno v:
Pediatric Dermatology
Background/Objectives Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild‐to‐moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::952ff611dd5cbeb0967aa859501efed0
https://pubmed.ncbi.nlm.nih.gov/32981097
https://pubmed.ncbi.nlm.nih.gov/32981097
Autor:
Evan J. Lipson, Ragini R. Kudchadkar, Sunil Reddy, Tomoko Akaike, Thomas Olencki, William H. Sharfman, Philip Friedlander, Steven P. Fling, Mizuho Kalabis, Candice D. Church, Kari Kendra, Michi M. Shinohara, Adil Daud, Adam I. Riker, Harriet M. Kluger, Elad Sharon, Melissa Amber Burgess, Janis M. Taube, Paul Nghiem, Brent A. Hanks, Suzanne L. Topalian, Blanca Homet Moreno, Andrew S. Brohl, Brian C. Boulmay, Martin A. Cheever, Bob Salim, Erin Jensen, Shailender Bhatia, Nirasha Ramchurren
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
BackgroundMerkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272adca2addf0d58650483b69b745a95
https://doi.org/10.1136/jitc-2021-002478
https://doi.org/10.1136/jitc-2021-002478
Autor:
Elliot Chartash, Lokesh Jain, Dinesh P. de Alwis, Mallika Lala, Shu-Chih Su, Omobolaji Oyekunle Akala, Mizuho Kalabis, Vikram Sinha
Publikováno v:
Cancer Research. 80:CT042-CT042
Background: Pembrolizumab is approved globally in multiple cancer indications at a dose of 200 mg or 2 mg/kg every three weeks (Q3W). An alternative dosing regimen of 400 mg every six weeks (Q6W), which provides convenience and flexibility to patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d8ef5ccc60934dcfca3fe1cc81b3fcf
https://doi.org/10.1158/1538-7445.am2020-ct042
https://doi.org/10.1158/1538-7445.am2020-ct042
Autor:
Nicholas J. Petrelli, Michela Perego, Marilda Beqiri, Mizuho Kalabis, Denitsa Hristova, Rajasekharan Somasundaram, Min Xiao, Clemens Krepler, Meenhard Herlyn
Publikováno v:
Clinical Cancer Research. 22:PR02-PR02
Melanoma patients develop resistance to both chemo- and targeted-therapy drugs. Promising pre-clinical and clinical results with immune checkpoint inhibitors using antibodies directed against CTLA4 and PD1 have re-energized the field of immune-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d0506b5ced6fd89f03d0cb8c5ceeff4
https://doi.org/10.1158/1557-3265.pdx16-pr02
https://doi.org/10.1158/1557-3265.pdx16-pr02